#Health / Well-being #Scientific Instrumentation
- In vitro diagnostics
- Clinical biochemistry
- Electrophoresis
- Instruments
- Reagents
- Monoclonal gammopathies, Hemoglobinopathies, Diabetes
- Chronic alcohol abuse
As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.
Discover >Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.
Discover >Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.
Discover >#Health / Well-being #Scientific Instrumentation
Design, manufacture and commercialization of in vitro diagnostic systems (instruments and reagents) for medical biology laboratories.
BACKGROUND
Since its incorporation 50 years ago, SEBIA has become a global leader in innovative electrophoretic in vitro diagnostic systems and particularly in the field of capillary electrophoresis.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
Electrophoresis consists in the use of an electrical field to separate the proteins contained in biological samples. The most recent capillary electrophoresis technique is applied in the dedicated automated systems: the CAPILLARYS range (CAPILLARYS 2 Flex Piercing, CAPILLARYS 2 Neonat Fast and Capillarys 3) and MINICAP Flex Piercing.
The HYDRASYS range (ASSIST, HYDRASYS 2 SCAN, HYDRASYS 2 SCAN FOCUSING) utilizes an agarose gel as a support.
The electrophoresis technique is a leading technology in the diagnosis of immune system diseases such as myeloma, hemoglobin abnormalities, HbA1c and the detection of other protein markers.
CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
SEBIA’s R&D efforts are delivering results in two fields:
Moreover SEBIA offers high quality products and services throughout the world.
COLLABORATIONS SOUGHT
Sebia maintains close links with the medical community, including university labs associated with its research work and disease specialists developing applications. Sebia has also started collaborations with several associations involved in research projects that bring information and support to patients suffering from myeloma and to their families.
Annual turnover: €250M
> 700 staff members worldwide
Strengths:
World leader in the IVD field using the electrophoresis technology. Strong innovation capacity. Number 1 company for the diagnosis of monoclonal gammopathies. Major player in the fields of hemoglobin disorders and diabetes through the HbA1c test. High-level scientific and technical support. Education.
Innovation assets:
50 years of experience in electrophoresis technology. A renowned company worldwide for the diagnosis of multiple myeloma. Fully integrated company, with all the departments concentrated in Lisses (R&D, manufacturing, regulatory affairs, quality assurance, marketing, commercial, after sales service, scientific assistance and logistics).
Other facts:
Export represents more than 85% of Sebia’s sales turnover.
In same field